iTeos Therapeutics prsentiert vorlufige Daten der klinischen Studie A2A-005 sowie translationale und prklinische Daten zu Inupadenant auf dem ESMO-Kongress fr Immunonkologie
| ITOS Stock | USD 7.32 0.09 1.21% |
Slightly above 62% of Iteos Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Iteos Therapeutics suggests that many traders are alarmed. Iteos Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Iteos Therapeutics' earnings reports, geopolitical events, and overall market trends.
Iteos |
- Inupadenant CarboplatinPemetrexed in Phase-II-Studie A2A-005 zeigte eine Gesamtansprechrate von 63,9 percent und ein medianes...
Read at globenewswire.com
 |
Iteos Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Iteos Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Iteos Therapeutics Fundamental Analysis
We analyze Iteos Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Iteos Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Iteos Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earning
Price To Earning Comparative Analysis
Iteos Therapeutics is currently under evaluation in price to earning category among its peers. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Iteos Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Iteos Therapeutics stock to make a market-neutral strategy. Peer analysis of Iteos Therapeutics could also be used in its relative valuation, which is a method of valuing Iteos Therapeutics by comparing valuation metrics with similar companies.
Peers
Iteos Therapeutics Related Equities
| MLTX | MoonLake Immunotherapeuti | 1.78 | ||||
| DAWN | Day One | 0.23 | ||||
| APLS | Apellis Pharmaceuticals | 0.85 | ||||
| ANNX | Annexon | 1.33 | ||||
| TCRX | Tscan Therapeutics | 1.61 | ||||
| TERN | Terns Pharmaceuticals | 1.87 | ||||
| GLUE | Monte Rosa | 2.22 | ||||
| RVMD | Revolution Medicines | 2.38 | ||||
| BPMC | Blueprint Medicines | 2.42 | ||||
| ERAS | Erasca | 3.05 | ||||
| DSGN | Design Therapeutics | 3.70 | ||||
| KYMR | Kymera Therapeutics | 4.55 | ||||
| AMLX | Amylyx Pharmaceuticals | 4.91 | ||||
| SANA | Sana Biotechnology | 5.29 | ||||
| ABOS | Acumen Pharmaceuticals | 5.82 |
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.